Medication info

Starova Tablet 5 mg (Rosuvastatin Calcium)

Prescription medicationTabletApproval withdrawn
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
BC World Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/box [30 tablets (15 tablets/PTP (AluAlu) × 2)]
Approval status
Approval withdrawn

MFDS item code 201907231 · Approved 2019.10.15

This product's status changed to Approval withdrawn on 2024.11.13. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 ~ 17 years) The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Ingredients

Manufacturer
BC World Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia patients
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • stroke risk
  • myocardial infarction risk
View approved original text

This medication is used as an adjunct to dietary changes and exercise in patients with primary hypercholesterolemia and mixed dyslipidemia who do not achieve adequate control. It also helps patients with homozygous familial hypercholesterolemia in conjunction with diet or other therapies. It effectively lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis. It can also be used as an adjunct to diet in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia, and in those meeting specific criteria, it reduces cholesterol levels and decreases the risk of cardiovascular disease. It is also utilized as an adjunct in patients with primary dysbetalipoproteinemia. Additionally, it helps reduce the risk of stroke, myocardial infarction, and revascularization in middle-aged patients with elevated high-sensitivity C-reactive protein levels and cardiovascular disease risk factors.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 ~ 17 years) The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Precautions

This medication should not be used in certain patients. For instance, it should not be administered to patients with an allergy to any of its components, severely impaired liver function, muscle disorders, or significantly reduced kidney function. Women who are pregnant or breastfeeding, as well as women who may become pregnant, must utilize appropriate contraception to reduce pregnancy risk before using this medication, and caution is advised due to potential risks to the fetus. Patients at high risk of muscle-related disorders, such as those with moderately to severely impaired kidney function, reduced thyroid function, a family history of muscle disorders, previous muscle toxicity, alcoholics, and individuals of Asian descent, should avoid high doses of this medication or use it carefully. This medication contains lactose, so patients with lactose intolerance or related genetic conditions should not take it. It is essential to undergo regular liver function tests and muscle function tests while taking this medication. Particular caution is warranted for patients with a history of liver disease or those consuming alcohol excessively; any symptoms such as muscle pain, weakness, or cramps should be reported to healthcare professionals immediately. Furthermore, this medication can interact with other drugs, so patients should inform their healthcare providers of any concomitant medications. The combination with certain drugs may increase the blood concentration of this medication, raising the risk of muscle disorders. Pregnant or breastfeeding patients should not use this medication, and those planning to become pregnant should consult before use. In case of overdose, since there is no specific antidote, symptomatic treatment and monitoring of liver and muscle function is required. Finally, this medication may cause side effects such as dizziness, so caution is advised while driving or operating machinery.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, severe muscle weakness, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, elevated transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, drug-induced lichenoid rash, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, elevated ALT, chest pain, muscle cramps, gout, erectile dysfunction, elevated AST, numbness, dysesthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture. It is advisable to maintain the storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/box [30 tablets (15 tablets/PTP (AluAlu) × 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.